NASDAQ: ONCOOnconetix Inc Stock
$0.07+0.00 (+0%)
Updated May 8, 2025
ONCO Price
$0.07
Fair Value Price
N/A
Market Cap
$605.52k
52 Week Low
$0.05
52 Week High
$21.40
P/E
0x
P/B
0.02x
P/S
3.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.87M
Earnings
-$51.60M
Gross Margin
-39.1%
Operating Margin
-2,694.07%
Profit Margin
-2,758.7%
Debt to Equity
0.62
Operating Cash Flow
-$14M
Beta
0.7
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ONCO Overview
Blue Water Vaccines, Inc. is a biotechnology company developing vaccines for infectious diseases. The company's pipeline includes BWV-101, a flu vaccine, BWV-102, an H1 pre-pandemic vaccine, BWV-201, a streptococcus pneumoniae-induced acute otitis media vaccine, BWV-301, a norovirus-rotavirus vaccine, and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, OH.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ONCO's potential to beat the market
- ONCO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ONCO
RankedUnranked of 457
RankedUnranked of 457
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.89 | A | |
| $42.51 | A | |
| $8.11 | A |
Be the first to know about important ONCO news, forecast changes, insider trades & much more!
ONCO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ONCO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ONCO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ONCO is good value based on its book value relative to its share price (0.02x), compared to the US Biotechnology industry average (4.15x)
P/B vs Industry Valuation
ONCO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ONCO due diligence checks available for Premium users.
Valuation
ONCO fair value
Fair Value of ONCO stock based on Discounted Cash Flow (DCF)
Price
$0.07
Fair Value
-$0.30
Undervalued by
123.55%
ONCO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ONCO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-168.76x
Market
24.22x
ONCO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.02x
Industry
4.15x
ONCO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ONCO's financial health
Profit margin
Revenue
$406.9k
Net Income
-$3.8M
Profit Margin
-940.7%
ONCO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ONCO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$61.9M
Liabilities
$20.9M
Debt to equity
0.62
ONCO's short-term liabilities ($17.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONCO's long-term liabilities ($3.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONCO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
-$2.3k
Financing
$578.6k
ONCO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ONCO vs Biotech Stocks
Onconetix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.